Neural Noise

2026 week 09

34 min read

BCI Weekly Brief (week of 2026-02-23)

previous << weekly >> next

How this week was triaged

China’s brain-computer interface industry is racing ahead

TechCrunch - Biotech & Health

Score: 0.92

Published: 2026-02-22T16:00:00+00:00

Tags: BCI, industry, clinical, regulation

Direct coverage of BCI industry scaling, policy, clinical trials, and commercialization. China’s brain-computer interface industry is rapidly scaling from research to commercialization, driven by strong policy support, expanding clinical trials, and growing investor interest.

  • China’s BCI industry is rapidly moving from research to commercial scale, competing with U.S. leaders like Neuralink, backed by strong policy support, clinical trials, and investor interest.
  • Policy support includes provinces like Sichuan, Hubei, and Zhejiang setting medical pricing for BCI, speeding up insurance inclusion.
  • Market growth: Projected to reach $530 million (3.8 billion yuan) in 2025 and over 120 billion yuan by 2040.
  • Four key drivers:
    • Policy support: National roadmap targets milestones by 2027 and a full supply chain by 2030, with an 11.6 billion yuan ($165 million) brain science fund announced in 2025.
    • Clinical resources: Large patient pools and lower research costs accelerate trials, with national health insurance enabling faster commercialization.
    • Manufacturing maturity: Strong industrial base in semiconductors, AI, and medical hardware supports rapid R&D and prototyping.
    • Strategic investment: State-led and private capital surging, with notable deals like StairMed Technology ($48M Series B), BrainCo ($287M, IPO filed), and Gestala (angel round in talks).
  • Technological approaches:
    • Invasive BCIs: Implant electrodes for precise neuron-level signals (e.g., NeuroXess, Neuralink).
    • Noninvasive BCIs: Headsets/headbands using EEG for safety and ease (e.g., NeuroSky, BrainCo).
    • Emerging methods: Ultrasound, magnetoencephalography, optical methods, and hybrid BCIs.
  • Clinical progress: China completed its first fully implanted, wireless BCI trial (second globally) and over 50 flexible implantable BCI clinical trials by mid-2025.
  • Regulatory and ethical trends: Alignment with international standards, stricter oversight for invasive devices, and eased approval for noninvasive tech, with strengthened informed consent and broader ethics reviews.
  • Future vision: BCI seen as a bridge between human and AI intelligence, with potential for “human augmentation” beyond medicine.

Science Corp. and Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership - Business Wire

Google News (neural engineering)

Score: 0.92

Published: 2026-02-20T21:00:00+00:00

Tags: BCI, neural-engineering, industry, tier-1

Science Corp (neurotech) and Neurosoft Bioelectronics announced a BCI ecosystem partnership; directly relevant to device and interface roadmaps. Business Wire plus neural-engineering source; partnership is concrete implementation. Tier-1 for near-term ecosystem moves.

  • Partnership Announcement: Science Corporation and Neurosoft Bioelectronics partnered on February 20, 2026, to integrate Science’s world-class BCI tools with Neurosoft’s neural data platform.
  • Access Granted: Neurosoft gains access to Science’s full stack of clinical-grade neural recording tools, known as the Science BCI Ecosystem.
  • Purpose: Accelerate development of minimally invasive, fully implantable BCI systems for conditions like tinnitus and epilepsy, and scale high-fidelity neural data collection for Neurosoft’s foundation AI models.
  • Cost Efficiency: Enables first-in-human trials for under $5 million, compared to $75–100 million for independent development.
  • Leadership Quotes:
    • Max Hodak (Science CEO): Partnership enables innovators to focus on core solutions without rebuilding infrastructure.
    • Nicolas Vachicouras (Neurosoft CEO): Strategic move to accelerate clinical adoption and AI model development.
    • Darius Shahida (Science CSO): Neurosoft is the ideal partner to debut this model and advance BCI innovation.
  • Company Profiles:
    • Science Corporation: Focuses on restoring and extending life through neural engineering; known for PRIMA BCI retina implant.
    • Neurosoft Bioelectronics: Uses ultra-soft interfaces for full-cortical coverage and AI-driven neural data collection.
  • Industry Impact: Multiyear, multimillion-dollar agreement aims to reduce BCI development cost and complexity, fostering a community of innovators.

Science, Neurosoft partner on BCI tech - MassDevice

Google News (brain-computer interface)

Score: 0.88

Published: 2026-02-20T22:25:45+00:00

Tags: BCI, industry, med-device, tier-1

Same Science–Neurosoft BCI partnership covered in med-device press; decision-useful for device and regulatory watchers. MassDevice is credible for med-tech; supports tier-1 relevance.

  • Partnership: Science Corporation and Neurosoft Bioelectronics collaborate to integrate Science’s clinical-grade neural recording tools into Neurosoft’s BCI platform, aiming to accelerate development and reduce costs.
  • Science Corp. Technology: Prima BCI retinal implant (acquired from Pixium Vision in 2024), featuring a light-powered implant and glasses with a camera/projector; FDA breakthrough designation; submitted for U.S./EU approval in June 2025.
  • Neurosoft Technology: Ultra-soft, minimally invasive BCI systems using thin-film elastic electrodes; over a dozen human implants completed; targets tinnitus, epilepsy, and other neurological disorders.
  • Cost Impact: Partnership reduces first-in-human trial costs from $75–100M to under $5M by leveraging Science’s BCI stack.
  • Strategic Goals: Faster clinical adoption, scalable neural data collection for AI models, and reduced development complexity.
  • Leadership Quotes:
    • Max Hodak (Science): Focus on modular BCI tools to speed up innovation.
    • Nicolas Vachicouras (Neurosoft): Partnership accelerates therapies and AI model development.
    • Darius Shahida (Science): Neurosoft is the first of many planned collaborations to advance BCI therapies.

China brain computer interface outfit accelerates to human trials in quest to outpace Neuralink — mix of government backing and investor enthusiasm speeds time to market for NeuroXess - Tom’s Hardware

Google News (brain-computer interface)

Score: 0.88

Published: 2026-02-19T11:00:00+00:00

Tags: BCI, companies, clinical-trials, tier-1

NeuroXess moving to human trials with state and investor backing establishes a second major BCI development pole; direct competitive and regulatory signal for Western BCI. Tier-1 execution; Tom's Hardware is general-tech.

  • NeuroXess, a Shanghai-based BCI company founded in 2021, is advancing rapidly with Chinese government and investor support.
  • Enabled a paralyzed patient to control a computer cursor using their BCI just five days after the implant.
  • Uses invasive but non-penetrative technology: a polyimide and metal mesh that sits on the brain’s surface, avoiding tissue damage.
  • Contrasts with Neuralink, which uses microscopic threads that penetrate brain tissue, raising concerns about scarring and signal degradation.
  • Performance: NeuroXess achieved 5.2 bps in trials, while Neuralink reported 10 bps.
  • China’s government support and investor enthusiasm accelerate BCI development, potentially allowing it to overtake the U.S.
  • Focuses on medical applications, such as paralysis and ALS, due to the high-risk nature of brain implants.
  • Advances in invasive BCIs are expected to improve non-invasive systems, reducing the need for implants in the future.
  • China’s ecosystem creates a virtuous circle: more data, lower costs, and increased user adoption.

Tissue response to deep brain stimulation electrodes: a review of animal and neurohistopathological studies

Journal of Neural Engineering

Score: 0.88

Published: 2026-02-23T00:00:00+00:00

Tags: DBS, neuromodulation, neural-interface, tier-1

Core neuromodulation and neural-interface topic: DBS electrode–tissue interaction affects therapy; review of 33 cases (63 electrodes) plus animal data. Informs device design and chronic implantation. Peer-reviewed JNE; high relevance. tier-1.

  • Objective: Deep brain stimulation (DBS) is a widely used neuromodulation therapy for neurological and neuropsychiatric conditions, but questions remain about how brain tissue responds to DBS electrodes and its impact on therapy.
  • Approach: This review updates a previous neurohistopathological analysis, including studies up to the present, and examines 33 patient cases with 63 electrodes across various diseases and DBS targets, supplemented by animal studies.
  • Main Results: Findings highlight evidence from both human and animal studies to fill gaps where neurohistopathological data is lacking.
  • Significance: The review aims to guide future research and improve clinical outcomes by deepening the understanding of tissue responses to DBS electrodes.

Apple Wants People to Control Devices With Their Thoughts - MSN

Google News (synchron)

Score: 0.88

Published: 2026-02-20T01:34:10+00:00

Tags: BCI, consumer-neurotech, tier-1

Directly addresses consumer BCI and thought-based device control; surfaced via Synchron keyword so ties to invasive/BCI ecosystem. High near-term relevance for product and regulatory attention. Source is general news; technical depth unknown.

  • Apple is partnering with Synchron, an Australian neurotech startup, to develop brain-computer interface (BCI) technology for its devices.
  • Synchron’s implant is called the Stentrode — a stent-like device placed in a vein near the brain’s motor cortex via the jugular vein, requiring no open brain surgery.
  • The implant reads brain signals (motor intent) and translates them into device commands like selecting icons, opening apps, and composing messages.
  • Apple introduced a new BCI HID (Human Interface Device) protocol, formally recognizing neural input as a native input category alongside touch, voice, and typing.
  • The protocol is built into iOS 26, iPadOS 26, and visionOS, enabling thought-driven control of iPhone, iPad, Mac, and Apple Vision Pro.
  • Primary goal is accessibility — helping millions with ALS, spinal cord injuries, stroke, or severe paralysis interact with devices without physical movement or voice.
  • Mark Jackson, a patient with ALS, demonstrated controlling an iPad and Vision Pro entirely with his thoughts using the Stentrode implant.
  • Apple plans to open the BCI protocols to third-party developers.
  • Synchron has raised $145 million and completed two human clinical trials since 2019, with a larger-scale study planned.
  • The technology could receive commercial approval by ~2030, per Synchron CEO Tom Oxley.
  • The BCI industry is projected to grow rapidly, potentially becoming a trillion-dollar market within the next decade.

China’s brain-computer interface industry is racing ahead - TechCrunch

Google News (brain-computer interface)

Score: 0.85

Published: 2026-02-22T16:00:00+00:00

Tags: BCI, regulation, international, tier-1

China BCI industry and policy push; informs competitive and regulatory context for the next 12 months. TechCrunch is strong source; policy and trials are tangible.

  • China’s BCI industry is moving from research to commercialization, driven by startups, policy support, expanding clinical trials, and growing investor interest .
  • Phoenix Peng, co-founder of implantable BCI maker NeuroXess and noninvasive ultrasound BCI startup Gestala, sees BCI as “the ultimate bridge between carbon-based and silicon-based intelligence” .
  • Provinces like Sichuan, Hubei, and Zhejiang have already set medical service pricing for BCI, speeding inclusion in China’s national medical insurance system .
  • In August 2025, China’s industry ministry and six other agencies released a national BCI roadmap targeting major technical milestones by 2027, common standards, and a full supply chain by 2030 .
  • Four factors driving China’s progress: (1) strong policy support with cross-department collaboration; (2) vast clinical resources, large patient pools, and lower research costs; (3) mature industrial manufacturing in semiconductors, AI, and medical hardware; (4) strategic state-led and private investment .
  • China announced an 11.6 billion yuan (~$165M) brain science fund at the 2025 Shenzhen BCI Expo to support companies from research through commercialization .
  • China completed its first fully implanted, wireless BCI trial (only the second globally after Neuralink), allowing a paralyzed patient to control devices without external hardware .
  • Over 50 flexible implantable BCI clinical trials were completed in China by mid-2025, covering motor/language decoding, spinal cord reconstruction, and stroke rehab .
  • Key funding deals: StairMed raised $48M (Series B); BrainCo reportedly filed for Hong Kong IPO after raising $287M; Gestala (launched Jan 2026) is closing an angel round .
  • Major Chinese BCI players include NeuroXess, Neuracle, NeuralMatrix, BrainCo, Bo Rui Kang Tech, Aoyi Tech, Brainland Tech, and Zhiran Medical .
  • China’s BCI market was expected to exceed $530M in 2025 (up from ~$450M in 2024), with projections reaching 120 billion yuan by 2040 .
  • Two main BCI paths: invasive electrophysiological (e.g., NeuroXess, Neuralink) for precise signals but with surgery risks, and noninvasive (e.g., BrainCo, NeuroSky) using EEG for safety/ease of use .
  • Emerging approaches include ultrasound, magnetoencephalography, transcranial magnetic stimulation, optical methods, and hybrid BCIs .
  • Ultrasound BCIs (from Merge Labs backed by OpenAI, and Gestala) target chronic pain, stroke, and depression — Gestala’s early trials showed 50% pain score reduction in a single session .
  • Regulators are expected to tighten oversight of invasive devices and BCI-generated data, while easing approval for noninvasive technologies and aligning with international IEC/ISO/FDA standards .
  • Ethics plans include strengthened informed-consent requirements, broadened ethics review beyond medicine, and unified technical standards for clinical evaluation .

Neurosoft gains BCI ecosystem access in partnership first with Science Corporation - Medical Device Network

Google News (brain-computer interface)

Score: 0.82

Published: 2026-02-23T22:51:34+00:00

Tags: BCI, Science Corp, partnerships

Neurosoft’s first BCI partnership with Science Corp gives ecosystem access and advances a concrete device path; Medical Device Network is a credible medtech outlet. Takeaways: Science Corp expanding via partners, Neurosoft gains platform access, BCI value chain consolidating. Tier-1 execution signal.

  • Neurosoft Bioelectronics is the inaugural partner of Science Corporation’s BCI ecosystem, gaining access to Science’s full neural recording technology stack .
  • Neurosoft develops soft brain electrodes for stimulation-based therapies targeting chronic pain and epilepsy .
  • Science Corporation’s BCI ecosystem (launched 2024) provides industry peers with tools to collect, process, and analyze neural BCI data — reducing development costs to roughly 1/20th of the typical $100M+ needed to build a full-stack clinical-grade BCI platform .
  • The partnership is a multiyear, multimillion-dollar agreement, though specific financial terms were not disclosed .
  • Science’s ecosystem tools include: Science Nexus (a software framework for defining/running behavioral experiments) and Synapse (a standardized API for communication protocols in BCI products like closed-loop neuromodulation and retinal visual prostheses) .
  • Neurosoft CEO Nicolas Vachicouras said the deal “aggressively accelerates clinical adoption” and rapidly scales high-fidelity neural data collection essential for powering Neurosoft’s foundation AI models .
  • Science CEO Max Hodak emphasized providing “robust, modular building blocks” so BCI innovators can develop therapies without rebuilding fundamental infrastructure .
  • The global neurology devices market is projected to exceed $25B by 2034 (per GlobalData) .
  • Morgan Stanley estimates BCI’s early TAM at $80B across 3 million US adults, potentially reaching $320B with further advancements .
  • Neuralink expects FDA approval for its Telepathy implant by 2029, targeting $1B in revenue by 2031 after implanting 20,000 patients .
  • OpenAI and other major tech players are also eyeing the BCI space .

Ultrasound transcutaneous auricular vagus nerve stimulation enhances semantic processing

bioRxiv Neuroscience

Score: 0.82

Published: 2026-02-23T00:00:00+00:00

Tags: neuromodulation, taVNS, methods

Non-invasive neuromodulation (ultrasound taVNS) shown to improve semantic retrieval in healthy adults in a sham-controlled design. Relevant for stimulation methods and cognitive enhancement. Preprint; clear methods.

Here’s the flat summary:

  • Authors: Yoonjin Kang, Marcus Kaiser, and JeYoung Jung.
  • Topic: First study to test whether ultrasound-based transcutaneous auricular vagus nerve stimulation (taVNS) can enhance semantic processing (i.e., the brain’s ability to retrieve conceptual/word meaning).
  • Method: Single-blind, sham-controlled, within-subject design with 27 healthy adults completing two counterbalanced sessions (active vs. sham) separated by ≥5 days.
  • Stimulation: Ultrasound-based taVNS delivered to the right cymba conchae (a region of the outer ear innervated by vagal afferents) for 30 minutes per session.
  • Tasks: Participants performed a semantic association task and a number-judgement control task before and immediately after stimulation.
  • Key finding: Active taVNS produced selective improvements in semantic retrieval performance relative to both sham and baseline — the number-judgement control task showed no change, confirming domain specificity.
  • Safety: Adverse effects were minimal and did not differ between active and sham conditions.
  • Significance: Provides causal evidence that ultrasound taVNS acutely improves semantic processing efficiency, extending the known cognitive effects of taVNS beyond episodic and emotional memory.
  • Broader implication: Supports taVNS as a scalable, non-invasive approach for memory enhancement.
  • Conflict of interest: M. Kaiser is on the Scientific Advisory Board of NeurGear Inc. (Rochester, NY); the company had no involvement in the study.

Neurosoft partners with Science Corp. to advance BCI system - BioWorld MedTech

Google News (brain-computer interface)

Score: 0.80

Published: 2026-02-23T17:00:00+00:00

Tags: BCI, neuroprosthetics

Same deal as above; BioWorld MedTech is high-signal for device development. Takeaways: partnership framed as advancing a BCI system (not just ecosystem); strong fit for device and trial watchers.

  • Neurosoft Bioelectronics (Geneva) is the first partner of Science Corporation’s (Alameda, CA) BCI Ecosystem program, announced February 20, 2026.
  • Neurosoft develops minimally invasive, fully implantable BCI systems using ultra-soft, flexible cortical probes for tinnitus, epilepsy, and other neurological disorders.
  • Neurosoft’s probes have already been used in ~12 human patients.
  • Science Corp’s BCI Ecosystem (launched October 2024) provides a full-stack neural engineering platform — electronics, software, data interfaces, and calibration systems — so partners don’t have to build from scratch.
  • Building a full-stack clinical-grade BCI platform typically costs $75–100M; the Ecosystem enables first-in-human trials for under $5M and in a fraction of the time.
  • The deal is a multiyear, multimillion-dollar agreement (specific financials undisclosed).
  • Key Ecosystem tools include: Science Nexus (software framework for behavioral experiments) and Synapse (standardized API for BCI communication protocols including closed-loop neuromodulation and retinal prostheses).
  • Neurosoft’s dual purpose: clinical implants treat neurological disorders while simultaneously collecting high-fidelity, full-cortical-coverage neural data to train a foundation AI model of the brain.
  • Long-term vision: use that AI model to translate noisy signals from everyday wearables into precise human intent, bridging implants to mass-market, noninvasive BCIs.
  • Science Corp is known for its PRIMA retinal implant (restoring vision in clinical trials) and biohybrid BCI work; led by Max Hodak (Neuralink cofounder).
  • Science Corp raised $230M in a Series C (Lightspeed, Khosla, Y Combinator, IQT, Quiet Capital), bringing total capital to ~$490M.
  • Science expects Neurosoft to be “the first of many” Ecosystem partners, per CSO Darius Shahida.

Neurotechnology deserves an EU research moonshot - Science|Business

Google News (neurotechnology)

Score: 0.78

Published: 2026-02-19T11:33:39+00:00

Tags: neurotechnology, policy

EU push for a neurotechnology moonshot would shape funding and roadmaps for BCI and neural engineering over 5–10 years. Policy/strategy; Science|Business credible; implementation multi-year.

  • Author: Paweł Świeboda, affiliated with the Centre for Future Generations (CFG), argues neurotechnology should be a formal EU research “moonshot” in the next funding cycle.
  • Core problem: Europe has a strong neuroscience research base, but neurotechnology innovation is scattered across broad, undifferentiated EU funding streams with no dedicated strategy.
  • The US and China are moving deliberately — China aims to lead globally by 2030; the US has Neuralink, Synchron, and major private capital flowing in — while Europe risks falling behind.
  • Consumer neurotech firms now outnumber medical ones (60% of the ~300 global neurotech companies), and they face minimal regulatory barriers compared to medical devices.
  • Świeboda’s three-pronged proposal for the EU:
    1. Maximize pre-competitive collaboration — establish an EU Neurotechnology Medicine Platform (EU-NMP) to create synergies across fragmented research efforts
    2. Create a Neurotechnology Funding Board — adapt existing funding instruments and develop new ones (e.g., a Neurotechnology Joint Undertaking) tailored to neurotech’s unique needs
    3. Develop neurotechnology-specific reimbursement models — pool schemes across member states to enable companies to scale
  • Neurotechnology should be included among Europe’s new “moonshot” projects in the 2028–2035 Multiannual Financial Framework (FP10), potentially integrated with the proposed moonshot on innovative therapies for human regeneration.
  • Regulatory harmonization is urgently needed: cross-border alignment on clinical trial pathways, EU MDR revision (current form burdens innovation), and coordinated reimbursement.
  • Ethical governance is also on the agenda: the European Charter for Responsible Development of Neurotechnologies (led by the European Brain Council) and UNESCO’s first global normative framework were recently adopted, but concrete policy implementation is still pending.
  • Applications cited: stroke rehabilitation, Parkinson’s disease, epilepsy, chronic pain, major depression, and emerging consumer wellness/cognitive-enhancement devices.

Integrating neural, physiological, and interoceptive measures in social interaction

Frontiers in Neuroscience

Score: 0.76

Published: 2026-02-23T00:00:00+00:00

Tags: hyperscanning, neuroimaging, methods

Hyperscanning and inter-brain synchrony with physiological and interoceptive signals; supports multimodal neural/physiological time-series and coupling metrics. Methods-relevant for BCI/neurofeedback. Peer-reviewed; conceptual.

  • Author: Giada Lettieri, IMT School for Advanced Studies Lucca, Italy. Published in Frontiers in Neuroscience (Decision Neuroscience section), February 23, 2026 .
  • Type: Perspective article (conceptual/theoretical, not an empirical study) .
  • Core argument: Social interaction is not just “two brains meeting” — it’s the emergent product of continuously coupled brain-body systems within and between individuals .
  • Hyperscanning (simultaneous neural recording from 2+ people) has shown that partners’ brains synchronize during cooperation, conversation, and joint attention — but neural data alone can’t reveal emotional alignment, arousal, or regulatory strategies .
  • Physiological synchrony (heart rate, skin conductance, respiration) also converges between interacting partners and tracks rapport, cohesion, and cooperative success .
  • Interoception (sensing internal bodily signals like heartbeat and breathing) is proposed as the conceptual bridge between neural and autonomic levels — it shapes emotional experience, empathy, and self-other distinction .
  • Atypical interoceptive processing is implicated in autism, anxiety, and depression, all conditions marked by social difficulties .
  • Directing attention to bodily rhythms (e.g., breath-focused tasks) can enhance both autonomic and neural alignment between partners during hyperscanning .
  • Key methodological proposal: combine EEG/fNIRS with ECG, electrodermal activity, respiration, and facial EMG simultaneously during naturalistic interactive tasks, using temporally sensitive analyses .
  • Challenge: these signals operate on different timescales (neural = milliseconds; respiration = seconds; autonomic = tens of seconds; self-report = minutes), requiring multiscale analytic approaches .
  • Neural, physiological, and motor synchrony are often weakly correlated or dissociated — they should not be treated as indexing a single underlying process but as complementary dimensions .
  • Scaling beyond dyads: group-level cardiac synchrony (classrooms, teams, ensembles) predicts cohesion and collective performance .
  • Clinical applications: multimodal synchrony could serve as a biomarker of therapeutic engagement; interventions like breath-based attention, biofeedback, mindfulness, and vagal stimulation may stabilize internal dynamics and improve social coordination .
  • Developmental roots: parent-infant biobehavioral synchrony (heart rate, vagal tone, gaze) predicts self-regulation, empathy, and language outcomes years later .
  • Funded by: Fundação Bial and EU Next Generation (MSCA project VIBE) .

China Fast-Tracks Brain-Computer Interface Industry - findarticles.com

Google News (brain-computer interface)

Score: 0.75

Published: 2026-02-22T17:01:48+00:00

Tags: BCI, regulation, international, tier-1

China fast-tracking BCI industry; policy and market context. Overlaps with other China BCI items; findarticles is aggregator.

  • China’s BCI industry is shifting from lab experiments to real-world deployment, driven by national policy, insurance incentives, clinical pipelines, and advanced manufacturing .
  • A national BCI roadmap (released by the Ministry of Industry and 6 other agencies) targets technical milestones by 2027, common standards, and a full supply chain by 2030 .
  • Provinces (Sichuan, Hubei, Zhejiang) have set medical service pricing for BCI procedures — an early step toward national insurance reimbursement, which could rapidly unlock hospital adoption .
  • China completed its first fully implanted, wireless BCI trial (only the second globally after Neuralink), enabling a paralyzed patient to control devices without external hardware .
  • 50+ flexible implantable BCI clinical studies were completed by mid-2025, covering motor/language decoding, spinal cord reconstruction, and stroke rehab .
  • Two main BCI tracks: invasive (NeuroXess, Neuralink-style) for neuron-level precision but requiring surgery; noninvasive (BrainCo, NeuroSky) for safer, faster scaling across rehab, attention training, and mood disorders .
  • Next-gen modalities gaining traction: ultrasound, magnetoencephalography, optical techniques, transcranial magnetic stimulation, and hybrid approaches .
  • Key funding deals: StairMed raised $48M (Series B); BrainCo filed for Hong Kong IPO after raising $287M .
  • Major players: NeuroXess, Neuracle, NeuralMatrix, BrainCo, Bo Rui Kang Tech, Aoyi Tech, Brainland Tech, Zhiran Medical .
  • Ultrasound BCI startups (Gestala, Merge Labs) target chronic pain, stroke, depression; early pilot data showed 50% pain score reduction in a single session lasting 1–2 weeks .
  • Investor thesis shifting: HongShan Capital emphasizes long-term implant performance, biocompatibility, and manufacturing reliability over flashy demos — the focus is on building regulated, reimbursable products with durable unit economics .
  • China’s manufacturing edge in flexible electronics, precision machining, and medical device assembly compresses design-to-pilot production timelines .
  • Regulators aligning with IEC/ISO/FDA frameworks; expect tighter oversight of invasive systems, stricter neural data sovereignty rules, and streamlined pathways for noninvasive devices .
  • Market size: projected to exceed $530M in 2025, with long-range estimates topping 120 billion yuan (~$17B) by 2040 .
  • Ethics priorities: stronger informed consent, broader ethics review beyond hospitals, and unified clinical evaluation standards .

Note: This FindArticles piece covers substantially the same ground as the TechCrunch article, with additional detail on manufacturing advantages, investor thesis, and reimbursement dynamics.

Task-guided accelerated cTBS simultaneously treats depression and social dysfunction in patients with major depressive disorder: a randomized clinical trial - Nature

Google News (transcranial stimulation)

Score: 0.75

Published: 2026-02-20T15:12:25+00:00

Tags: transcranial-stimulation, neuromodulation, clinical

Nature RCT of task-guided accelerated cTBS for MDD; transcranial stimulation and neuromodulation with clinical endpoints. Takeaways: accelerated cTBS protocol can target both depression and social function; supports protocol optimization for TMS. Strong source and design; implementation is clinical TMS.

  • Published: February 20, 2026, in Neuropsychopharmacology (online ahead of print).
  • Authors: Jing Jin, Yun Wang, et al., from Beijing Anding Hospital / Capital Medical University, Chinese Academy of Sciences, Australian National University, and UCL.
  • Problem: Current antidepressants focus on symptom remission in MDD but largely overlook social dysfunction, a critical barrier to functional recovery.
  • Intervention: Individualized accelerated continuous theta burst stimulation (cTBS) targeting the right dorsolateral prefrontal cortex (R.DLPFC).
  • Personalization method: Stimulation sites were identified per patient using task-evoked brain activation during a social interactive task (Ultimatum Game).
  • Design: Randomized, double-blind, sham-controlled trial; 70 MDD patients (37 active, 33 sham); 2-week treatment.
  • Key results:
    • Active cTBS significantly reduced depressive and anxiety symptoms vs. sham (all p < 0.001)
    • Active cTBS improved general social functioning vs. sham (p < 0.001)
    • Active group showed enhanced cooperation behavior (p = 0.002) and increased learning rates (89% HDI: [0.01, 0.21])
  • Neural mechanism: Active cTBS increased effective connectivity from right insula → R.DLPFC and stabilized connectivity from ACC → left insula, differing from sham (posterior probability > 0.95).
  • Safety: No severe adverse events in either group.
  • Takeaway: Task-guided, personalized accelerated cTBS can simultaneously treat depression symptoms and social dysfunction in MDD, with connectivity changes in the DLPFC–insula–ACC network offering a mechanistic explanation.
  • Funding: National Natural Science Foundation of China.
  • Trial registration: ChiCTR2300068273.

A depression treatment that once took eight weeks may work just as well in one - UCLA Health

Google News (transcranial stimulation)

Score: 0.72

Published: 2026-02-24T02:04:25+00:00

Tags: transcranial-stimulation, neuromodulation, clinical

Accelerated depression protocol (likely intensive TMS/neuromodulation) from 8 weeks to 1 week; relevant to transcranial stimulation and clinical adoption. UCLA Health; clinical evidence implied.

  • UCLA Health researchers found that accelerated TMS (5 sessions/day × 5 days) may produce comparable depression relief to the standard 6–8 week protocol .
  • Published in: Journal of Affective Disorders .
  • Standard TMS: 1 session/day, 5 days/week, for 6 weeks — effective but burdensome; reduces symptoms in 60–70% of treatment-resistant patients, with 25–35% achieving remission .
  • Accelerated “5×5” protocol: 5 sessions/day for 5 consecutive days (25 total sessions in one week) .
  • Study design: Retrospective comparison (not a randomized trial) of 175 treatment-resistant depression patients — 135 received conventional TMS, 40 received the accelerated protocol .
  • Key finding: Both groups showed meaningful reductions in depression symptoms with no statistically significant difference in outcomes .
  • Delayed responders: Some accelerated-group patients who showed little improvement immediately after 5 days had a 36% average reduction in depression scores at 2–4 week follow-up .
  • Clinical implication: Patients who don’t feel better right after the 5-day course should not give up — benefits may emerge in the following weeks .
  • Conventional TMS still outperformed accelerated TMS on some longer-term measures .
  • Lead author: Michael Apostol, PhD student, UCLA Semel Institute; Senior author: Dr. Andrew Leuchter, director of UCLA’s TMS Service .
  • Limitations: Not a randomized clinical trial; larger controlled studies needed to confirm .
  • UCLA is also exploring TMS for OCD and chronic pain as part of next-generation brain-based therapies .

Science & PINS Prize for Neuromodulation - Science | AAAS

Google News (neuromodulation)

Score: 0.58

Published: 2026-02-19T16:47:01+00:00

Tags: neuromodulation, prize

Science and PINS prize for neuromodulation; signals field recognition and funding visibility. High source quality (Science/AAAS); prize is indirect for near-term execution.

  • The Science & PINS Prize for Neuromodulation is an annual award jointly presented by the journal Science (AAAS) and Beijing PINS Medical Equipment Co. Ltd.
  • Established in 2016, it recognizes innovative research at the intersection of engineering and clinical neurology.
  • Focus: Research that modulates neural activity through physical stimulation (electrical, magnetic, optical) of targeted nervous system sites, with implications for translational medicine.
  • Grand Prize: $25,000 USD + winner’s essay published in Science; Runner-up: $5,000 USD + essay published on Science Online.
  • Eligibility: Junior investigators only — must hold an advanced degree received in the last 10 years and be 45 years or younger as of January 1 of the award year.
  • Entry: A 1,000-word essay describing the applicant’s research and its implications, with up to 1 figure and 15 references; AI-generated text is prohibited.
  • 2026 submission deadline: March 15, 2026 (6 days from now).
  • Timeline: Entries close mid-March → judged by Science/Science Translational Medicine editors → winner selected June/July → announced and presented at a ceremony ~August/September.
  • 2025 winner: Newton Cho (University of Toronto neurosurgery), recognized for identifying a novel therapeutic target via neuromodulation.
  • Past winners span 2016–2025, listed on the Science website.

Acceptability of remotely supervised Home-Based transcranial direct current stimulation combined with Cognitive-behavioural-based app for peripartum depression: perspectives from women with lived experience and mental health professionals - Nature

Google News (tDCS)

Score: 0.56

Published: 2026-02-23T10:42:13+00:00

Tags: tDCS, clinical

tDCS is in-scope; this piece focuses on acceptability and remote supervision for peripartum depression. Takeaway: at-home tDCS plus app is feasible from user/professional perspective. Down-weighted for psychiatry-first framing. Nature;

  • Title: “Acceptability of remotely supervised Home-Based transcranial direct current stimulation combined with Cognitive-behavioural-based app for peripartum depression”.
  • Published: February 23, 2026, in Scientific Reports (Nature).
  • Authors: Ana Ganho-Ávila, Andreia Cruz, Nina Szczygiel, Ana Tomás, Catarina Azevedo, Pedro Bastos, Mariana Moura-Ramos — University of Coimbra, Portugal.
  • Problem: Peripartum depression (PPD) affects ~20% of women globally, but existing treatments (antidepressants, in-person therapy) face significant uptake barriers — medication concerns during pregnancy/breastfeeding, stigma, childcare logistics.
  • Intervention studied: The FLOW Neuroscience solution — a wearable transcranial direct current stimulation (tDCS) headband combined with a CBT-based smartphone app, designed for home use under remote professional supervision.
  • Design: Qualitative focus group study using the Theoretical Framework of Acceptability (TFA) — not a clinical efficacy trial.
  • Participants: 15 women with lived experience of PPD (experts by experience, EEs) and 14 healthcare professionals (HPs).
  • Overall reception: Both groups were generally positive, viewing the solution as supporting patient autonomy, freedom of choice, and universal access to perinatal mental healthcare.
  • Key concerns raised:
    • Exclusively remote/virtual and bot-led interventions may reduce stigma but could also increase loneliness in depressed patients
    • Need for effective communication strategies to build trust in health innovation
    • Should be integrated into existing care models, not used as a standalone replacement
  • Takeaway: The FLOW solution addresses real gaps in PPD care but has limitations; the study provides user-centered, actionable design insights to improve access and engagement.
  • Funding: Fundação para a Ciência e a Tecnologia (Portugal) and FLOW Neuroscience.
  • Conflicts: Lead author reports receiving loaned equipment from Sooma Medical and Flow Neuroscience; serves on European Society for Brain Stimulation committee.

Multimodal PET/MR imaging of prolonged disorders of consciousness: a pilot feasibility study

Frontiers in Neuroscience

Score: 0.52

Published: 2026-02-20T00:00:00+00:00

Tags: neuroimaging, clinical, methods

Pilot on PET/MR in pDOC with fMRI, DTI, FDG-PET for neural biomarkers and behavioral responsiveness. Relevant for neuroimaging and prognostic biomarkers in severe brain injury; no electrophysiology. Feasibility design; tneuroimaging methods.

  • Title: “Multimodal PET/MR imaging of prolonged disorders of consciousness: a pilot feasibility study” .
  • Published: February 19, 2026, in Frontiers in Neuroscience (Brain Imaging Methods section) .
  • Authors: Ning Sun, YiWei Liu, Hua Lin, et al. — West China Hospital, Sichuan University, Chengdu, China .
  • Aim: Test the feasibility of simultaneous 18F-FDG PET/MR to characterize metabolic, functional, and structural brain alterations in prolonged disorders of consciousness (pDOC) .
  • Participants: 8 pDOC patients (4 coma, 1 VS/UWS, 3 MCS; mean age 50.1; etiologies: intracerebral hemorrhage, brain tumor, hypoxic-ischemic encephalopathy) and 8 matched healthy controls .
  • Modalities acquired simultaneously: resting-state fMRI (ALFF), FDG-PET (glucose metabolism), and DTI (white matter integrity/FA) .
  • Key findings :
    • Reduced ALFF and FDG uptake in the posterior cingulate cortex (PCC) and anterior cingulate cortex (ACC) in pDOC vs. controls
    • Paradoxically increased ALFF in primary visual cortex — inversely correlated with CRS-R visual subscores (worse visual responsiveness = higher spontaneous activity), likely reflecting disorganized activity in a deafferented region, not preserved visual processing
    • Attenuated intraand inter-network connectivity in default mode network (DMN), salience network (SN), and dorsal attention network (DAN)
    • Metabolic hypofunction in insula, frontal cortex, and cerebellum; some cerebellar areas showed increased metabolism (possible compensation)
    • Widespread white matter FA reductions across nearly all major tracts (anterior thalamic radiations, corticospinal tracts, cingulum, longitudinal fasciculi, etc.)
  • Multimodal convergence: PCC and occipital regions showed overlapping abnormalities across PET, fMRI, and DTI — identified as candidate hubs for consciousness .
  • Structure-function dissociation: Widespread white matter damage only partially corresponded to functional disconnection — some patients had severe DTI abnormalities but residual cortical activity .
  • Limitations: Very small sample (n=8 per group), cross-sectional, single-center, heterogeneous etiologies and post-injury intervals; findings are exploratory .
  • Clinical implication: Simultaneous PET/MR is feasible in severely brain-injured patients and could complement behavioral scales (like CRS-R) to reduce diagnostic misclassification, but needs validation in larger multicenter studies .

Global Neuromodulation Devices Market Anticipating Remarkable Growth at a CAGR of ~9% by 2032 | DelveInsight - GlobeNewswire

Google News (neuromodulation)

Score: 0.48

Published: 2026-02-23T18:00:00+00:00

Tags: neuromodulation, market

Broad neuromodulation market forecast to 2032 (~9% CAGR) is decision-useful for market sizing; DelveInsight is standard for industry reports. Takeaways: long-horizon growth, includes stim devices (tDCS/tACS/DBS etc.).

  • Source: DelveInsight market research report, published via GlobeNewsWire on February 23, 2026 .
  • 2024 global neuromodulation devices market size: $7.8 billion .
  • 2032 projected market size: $16.1 billion at a CAGR of ~9% (2025–2032) .
  • Largest market: North America (~55% share in 2024), driven by the US .
  • Second largest: Europe (~21% share in 2024) .
  • Fastest-growing region: Asia-Pacific, with a projected CAGR exceeding 12% .
  • Largest device segment: Spinal cord stimulators .
  • Other segments: Deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators .
  • Key growth drivers :
    • Rising prevalence of chronic pain, epilepsy, Parkinson’s, treatment-resistant depression
    • Technological advances (miniaturization, closed-loop systems, rechargeable/non-invasive devices)
    • Growing geriatric population globally
    • Favorable regulatory and reimbursement policies
    • Patient preference for minimally invasive, drug-free alternatives
  • Recent milestones :
    • Jan 2026: FDA cleared ProlivRx (Neurolief) — first prescription at-home neuromodulation for depression
    • Sep 2025: Vivani Medical spun off Cortigent for brain implant development
    • Jun 2025: Neuspera Medical iSNM system FDA-approved for urinary incontinence (batteryless)
    • Mar 2025: Newronika AlphaDBS (closed-loop adaptive DBS) received CE Mark
    • Feb 2025: FDA approved Medtronic BrainSense adaptive DBS for Parkinson’s — first of its kind
  • Key companies: Medtronic, Abbott, Boston Scientific, Nevro, LivaNova, Stryker, ElectroCore, Stimwave, Aleva Neurotherapeutics, among others .

What’s the age of your brain? Neurotechnology study by Colorado doctor has the answer. - CBS News

Google News (neurotechnology)

Score: 0.42

Published: 2026-02-20T15:10:52+00:00

Tags: neurotechnology, neuroimaging

Neurotechnology study on brain age; tangential to BCI (likely neuroimaging/ML). CBS is general audience; methods unclear from title—down-weighted for electrophysiology focus.

  • Dr. Sean Pauzauskie, a neurologist at UCHealth (Colorado), is using consumer neurotechnology wearables — including headphones with medical-grade brain sensors — to study amnesia, dementia, epilepsy, and brain fog .
  • AI-powered brainwave analysis can now decipher encrypted patterns in brain waves that change with age, enabling a “brain age” measurement .
  • If measured brain age exceeds biological age, the patient may be a candidate for early intervention to slow or prevent dementia and Alzheimer’s .
  • Seizure prediction: Pauzauskie’s team is identifying brainwave patterns that predict when seizures are about to start — potentially a “game changer” for health and public safety .
  • The Muse device uses electrical stimulation and neurofeedback to rewire specific brain regions; Pauzauskie is studying it for brain fog, depression, anxiety, addiction, and phobias .
  • Other consumer neurotech devices mentioned: music-based mood regulators, light-based creativity enhancers, hands-free phone/computer control glasses, and sensory shoes for mind-body stimulation .
  • Privacy concerns: the ability to identify brain wave frequencies tied to specific conditions raises ethical issues when private companies access that data .
  • Colorado passed a first-in-the-nation law (2 years ago) expanding the state’s privacy act to cover neural/brain data — Pauzauskie led this effort as Medical Director of the Neurorights Foundation .
  • Federal legislation: A US Senate bill called the MIND Act (Management of Individuals’ Neural Data) aims to protect neural data nationally; Pauzauskie helped draft it .
  • Pauzauskie is also working on similar brain-data privacy bills in other states .

A case–control neuroimaging investigation of chronic Zika virus-infected adults

Frontiers in Human Neuroscience

Score: 0.42

Published: 2026-02-20T00:00:00+00:00

Tags: neuroimaging, human-neuroscience

Adult ZIKV cohort with structural and resting-state connectivity; human neuroscience and neuroimaging methods. Informs long-term CNS effects and connectivity metrics. No BCI or electrophysiology; neuroimaging and CNS injury.

  • Title: “A case–control neuroimaging investigation of chronic Zika virus-infected adults” .
  • Published: February 20, 2026, in Frontiers in Human Neuroscience (Brain Imaging and Stimulation section) .
  • Authors: Suhnyoung Jun, Richard Bido-Medina, et al. — University of Illinois Urbana-Champaign (Beckman Institute), Harvard/MGH, CEDIMAT (Dominican Republic) .
  • Aim: First case–control neuroimaging study of the chronic-stage (5–12 months post-infection) effects of Zika virus on the adult brain .
  • Participants: 43 total — 14 ZIKV patients with both CNS symptoms and Guillain-Barré Syndrome (ZIKV-CNS-GBS), 15 non-ZIKV GBS patients (disease controls), and 14 healthy controls, all recruited in the Dominican Republic .
  • Imaging modalities (all on 3T Philips): T1-weighted cortical thickness, FLAIR white matter lesions, DTI (FA & MD), and resting-state fMRI (hippocampal seed-based + whole-brain connectivity) .
  • Key result: Null findings across all modalities — no significant group differences in cortical thickness, white matter hyperintensities, white matter microstructure, or functional connectivity .
  • Bayesian analysis provided moderate evidence in favor of the null (BF₀₁ = 3.94 for lesion volume; 4.57 for lesion number) .
  • Power: Analyses had 80% power to detect large effects (f ≈ 0.49–0.54); smaller or regionally specific effects could have been missed .
  • Clinical distinctiveness: ZIKV-CNS-GBS patients showed atypical GBS features — rapid para-infectious onset (mean 8.85 days), descending pattern in 5/14 patients, and prominent CNS symptoms (hemianopsia, dystonia, facial palsy, memory disturbances) .
  • Interpretation: Chronic ZIKV infection in adults does not appear to produce large-magnitude structural or functional brain changes — subacute-phase gray matter alterations (found in the authors’ earlier study) may reflect transient neuroinflammation that resolved over time .
  • Limitations: Very small sample due to extreme rarity of ZIKV-CNS-GBS; unmatched demographics; variable timing of chronic assessment; missing data in some modalities .
  • Takeaway: Despite null imaging results, severe clinical symptoms persist; the study underscores the need for longitudinal monitoring and care of adult ZIKV survivors, especially given ongoing outbreaks fueled by climate change .

Study connects vascular health to early Alzheimer’s brain changes - News-Medical

Google News (neuroimaging)

Score: 0.38

Published: 2026-02-24T03:07:00+00:00

Tags: neuroimaging

Vascular and early Alzheimer's brain changes inform neuroimaging and risk biomarkers; tangential to BCI. Down-weighted: no electrophysiology or interfaces.

  • Study: “Cerebrovascular regulation dynamics and Alzheimer’s neuroimaging phenotypes,” published in Alzheimer’s & Dementia (February 2026) .
  • Institution: Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, USC .
  • Lead author: Amaryllis A. Tsiknia (USC PhD candidate); Senior author: Meredith N. Braskie, PhD (assistant professor of neurology, Keck) .
  • Tools used: Transcranial Doppler ultrasound (blood flow velocity in brain arteries) + near-infrared spectroscopy (cortical tissue oxygenation) — both noninvasive, performed at rest .
  • Advanced mathematical models summarized vascular signals into indicators reflecting how well the brain adjusts blood flow and oxygen delivery in response to blood pressure and CO₂ changes .
  • Key finding: Higher (healthier) vascular indicator values were associated with lower amyloid plaque levels and larger hippocampal volume — both markers of reduced Alzheimer’s risk .
  • Participants with MCI or dementia had poorer vascular indicators than cognitively normal adults, reinforcing cerebrovascular decline as part of the Alzheimer’s continuum .
  • Implication: Vascular health may play an important role early in the Alzheimer’s disease process — potentially useful for identifying at-risk individuals before symptoms appear .
  • Practical advantage: These vascular measures are cheaper than MRI/PET, require no injections, radiation, or active patient participation — suitable for large-scale screening .
  • Limitation: Cross-sectional (snapshot in time); cannot prove causation .
  • Next steps: Longitudinal studies already underway to determine whether vascular changes predict future cognitive decline and whether improving vascular health can slow Alzheimer’s-related brain changes .

Music therapy in health care practice: promise, pitfalls, and policy implications

Frontiers in Human Neuroscience

Score: 0.38

Published: 2026-02-23T00:00:00+00:00

Tags: clinical, neurorehabilitation

Review touches neurological conditions (Parkinson's, stroke, TBI) but no neural interfaces or electrophysiology; clinical/therapeutic focus. Limited relevance to BCI/neurotech execution.

Here’s the flat summary:

  • Title: “Music therapy in health care practice: promise, pitfalls, and policy implications”.
  • Published: February 23, 2026, in Frontiers in Human Neuroscience (Cognitive Neuroscience section).
  • Authors: Yung-Yi Lan, Rujith Kovinthapillai, and others.
  • Type: Review article.
  • Core argument: Music therapy is a safe, effective, person-centered intervention bridging neuroscience, medicine, and humanities — but remains underutilized in mainstream clinical practice.
  • Strongest evidence base: Dementia care (cognitive stimulation, behavioral symptom management, quality of life).
  • Other conditions with expanding evidence: Parkinson’s disease, stroke, acquired/traumatic brain injury, schizophrenia, autism spectrum disorder, depression, insomnia, and palliative care.
  • Mechanisms of action: Music engages sensorimotor, cognitive, memory, and emotional brain networks; triggers neuroplasticity; modulates neuromodulators (dopamine, endorphins, oxytocin); and supports social bonding.
  • Implementation barriers:
    • Methodological heterogeneity across studies (inconsistent protocols, outcome measures)
    • Workforce shortages of credentialed music therapists
    • Limited insurance reimbursement
    • Resource disparities across settings and regions
    • Lack of streamlined referral mechanisms
    • Inadequate recognition as a standard clinical practice
  • Ethical challenges: Informed consent (especially in cognitively impaired populations), patient autonomy, and cultural sensitivity.
  • Policy recommendations:
    • Standardized reporting frameworks for music therapy research
    • Multidisciplinary collaboration to integrate music therapy into care teams
    • Equitable access policies across socioeconomic and geographic lines
    • Long-term cost-effectiveness and feasibility studies
    • Recognition of music therapy as reimbursable standard care
  • Broader context: Aging populations and rising chronic illness prevalence make scalable, non-pharmacological interventions like music therapy increasingly important for health system sustainability.

Graph View

Backlinks